http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Imunon%2C+Inc.+++++++++++++++++++++++++/26660118.html si-local-file:///var/storage/secattach/20260617/26660118.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Imunon%2C+Inc.+++++++++++++++++++++++++/26660118.html Wed, 17 Jun 2026 16:16:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Imunon%2C+Inc.+++++++++++++++++++++++++/26660118.html si-local-file:///var/storage/secattach/20260617/26660118.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Imunon%2C+Inc.+++++++++++++++++++++++++/26660118.html Wed, 17 Jun 2026 16:16:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+16/26655378.html si-local-file:///var/storage/secattach/20260616/26655378.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+16/26655378.html Tue, 16 Jun 2026 17:30:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+16/26655378.html si-local-file:///var/storage/secattach/20260616/26655378.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+16/26655378.html Tue, 16 Jun 2026 17:30:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Tardugno+Michael+H/26624781.html si-local-file:///var/storage/secattach/20260609/26624781.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Tardugno+Michael+H/26624781.html Tue, 09 Jun 2026 17:16:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Tardugno+Michael+H/26624781.html si-local-file:///var/storage/secattach/20260609/26624781.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Tardugno+Michael+H/26624781.html Tue, 09 Jun 2026 17:16:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Lindborg+Stacy/26623796.html si-local-file:///var/storage/secattach/20260609/26623796.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Lindborg+Stacy/26623796.html Tue, 09 Jun 2026 16:14:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Lindborg+Stacy/26623796.html si-local-file:///var/storage/secattach/20260609/26623796.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+05++Filed+by%3A+Lindborg+Stacy/26623796.html Tue, 09 Jun 2026 16:14:00 -0400 IMNN O.00728514 http://www.streetinsider.com/Corporate+News/IMUNON+secures+%2410+million+financing+for+ovarian+cancer+trial/26602787.html <p>IMUNON Inc. (NASDAQ: IMNN) announced it has entered into definitive agreements for $10 million in aggregate gross proceeds through a structured financing arrangement. The transaction includes $2.5 million from the issuance of 250 shares of non-redeemable, non-convertible preferred stock and $7.72 million from two secured promissory notes.</p><p>The promissory notes, with principal amounts of $2.72 million and $5.0 million, carry interest rates of 8% and 5% per annum respectively and mature 18 months after issuance. The company stated that interest will be partially offset with interest earned via bank deposit.</p><p>IMUNON plans to use the proceeds to support continued enrollment of its http://www.streetinsider.com/Corporate+News/IMUNON+secures+%2410+million+financing+for+ovarian+cancer+trial/26602787.html Thu, 04 Jun 2026 08:03:13 -0400 IMNN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+01/26602739.html si-local-file:///var/storage/secattach/20260604/26602739.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+01/26602739.html Thu, 04 Jun 2026 08:01:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+01/26602739.html si-local-file:///var/storage/secattach/20260604/26602739.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Imunon%2C+Inc.++++++++++++++For%3A+Jun+01/26602739.html Thu, 04 Jun 2026 08:01:00 -0400 IMNN O.00728514 http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Press+Releases/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html <p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br/>promissory notes for $7.72 million</p> <p align="center">Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</p> <p align="justify"><b>LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=VpYF3J2mdQPqfB2vfJE28DqfbAu3AKwZKSQH_iwOL4ZsGmR4T1OlLINbOPc1VY8kqtbroy3T3XBysN2JzNmlsNhK_hDQbUf6ClRb7fTZ5lYXItE4pn31bGsuqSS9TNEiiu6FfiavGOk5eHX0foBfmU4OpHZvpq8CPVpVlztJHG8g9whPUGcTsmyYpJrNwapgMnxY6gbRX9naw-wHnSIPZTu1YuzQsXVFu_T1MRVrVD4rf46vKzgCnAhqBs_6HgLrUoAD6FVO3l3lqC3q2A0d-OecYX0i8rs8Z7jVLaJYX8jVFnzfmRz_e9QCUSIdd9lbPAXEUzKn6NXpdz4Egcy8To21SqWaZuZn53p_7Rcvv0g=" rel="nofollow" target="_blank"><b>IMUNON</b></a><b>, Inc. (Nasdaq: IMNN)</b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible http://www.streetinsider.com/Globe+Newswire/IMUNON+Announces+Up+to+%2410+Million+Cash+Financing/26602597.html Thu, 04 Jun 2026 08:00:00 -0400 A.50209015 IMNN O.00225875 O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Tardugno+Michael+H/26558225.html si-local-file:///var/storage/secattach/20260527/26558225.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Tardugno+Michael+H/26558225.html Wed, 27 May 2026 16:22:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Tardugno+Michael+H/26558225.html si-local-file:///var/storage/secattach/20260527/26558225.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Tardugno+Michael+H/26558225.html Wed, 27 May 2026 16:22:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Dentzer+James+E/26557995.html si-local-file:///var/storage/secattach/20260527/26557995.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Dentzer+James+E/26557995.html Wed, 27 May 2026 16:13:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Dentzer+James+E/26557995.html si-local-file:///var/storage/secattach/20260527/26557995.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Dentzer+James+E/26557995.html Wed, 27 May 2026 16:13:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Pellizzari+Christine+A/26558003.html si-local-file:///var/storage/secattach/20260527/26558003.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Pellizzari+Christine+A/26558003.html Wed, 27 May 2026 16:13:00 -0400 IMNN O.00728514 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Pellizzari+Christine+A/26558003.html si-local-file:///var/storage/secattach/20260527/26558003.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Imunon%2C+Inc.++++++++++++++For%3A+May+22++Filed+by%3A+Pellizzari+Christine+A/26558003.html Wed, 27 May 2026 16:13:00 -0400 IMNN O.00728514